Balance Sheet

Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased Short-Term Debt issuances Short-Term Debt repayments

Daily Values

Growth Metrics

Biocryst Pharmaceuticals (BCRX) Other financing activities (2016 - 2026)

Biocryst Pharmaceuticals filings provide 8 years of Other financing activities readings, the most recent being $262000.0 for Q3 2023.

On a quarterly basis, Other financing activities changed N/A to $262000.0 in Q3 2023 year-over-year; TTM through Dec 2024 was $262000.0, a 0.0% change, with the full-year FY2023 number at $11.1 million, changed N/A from a year prior.
Other financing activities hit $262000.0 in Q3 2023 for Biocryst Pharmaceuticals, up from -$20000.0 in the prior quarter.
In the past five years, Other financing activities ranged from a high of $262000.0 in Q3 2023 to a low of $262000.0 in Q3 2023.